



HEALTHCARE

## **Building Biotech Technology Transfer Opportunities**

Sponsor and developer strategies for success

By Alison Sahoo

## **Alison Sahoo**

Alison Sahoo is a pharmaceutical industry analyst with more than 10 years of experience researching the development of medicines and medical devices. She holds a BS in Physics from McGill University and an MBA in International Business from Rutgers University. She has written on a large number of healthcare topics including allergies, aesthetic products and procedures, biopharmaceuticals, clinical nutrition, contract research and manufacturing, diabetes, diagnostic imaging, gastrointestinal disease, generics, healthcare financing, infection control, long term care, obesity, over-the-counter (OTC) medications, Rx-to-OTC switch, stroke management, vaccines and other subjects.

Copyright © 2010 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

# Table of Contents

## Building Biotech Technology Transfer Opportunities

<b>Executive Summary</b>	<b>8</b>	
<b>Overview of biotech tech transfer</b>	<b>8</b>	
<b>Why biotech tech transfer deals fail</b>	<b>9</b>	
<b>Strategies to ensure successful biotech tech transfer deals</b>	<b>10</b>	
<b>The future of biotech tech transfer deals</b>	<b>11</b>	
<b>Chapter 1</b>	<b>Overview of biotech tech transfer</b>	<b>14</b>
<b>Summary</b>		<b>14</b>
<b>The biotechnology industry today</b>		<b>15</b>
Biotechnology technologies and techniques		15
Proliferation of investigational products		18
Funding issues		18
Need to partner to advance product development		19
The emergence of biotechnology brokers		20
<b>Drug development challenges</b>		<b>21</b>
More complicated disease targets		22
Escalating costs		22
Increased regulatory scrutiny		23
Diminished in-house R&D resources		24
<b>Types of biotech tech transfer relationships</b>		<b>26</b>
Academic R&D infusions		28
Biotech biotech deals		29
Pharma biotech alliances		30
Licensing		32
R&D collaborations		33
Sales, distribution and co-marketing agreements		33
Joint ventures		33
Acquisitions		34
<b>Volume of recent deals</b>		<b>35</b>
<b>Relationship trends</b>		<b>51</b>
Volume and value		51

Ownership	52
<b>Conclusion</b>	<b>53</b>

## **Chapter 2                    Why biotech tech transfer deals fail                    56**

<b>Summary</b>	<b>56</b>
<b>High failure rates</b>	<b>57</b>
Symptoms of deal failure	57
Factors that do not affect deal failure	58
<b>Implications of deal failure</b>	<b>59</b>
Impact on technology developers	60
Impact on technology sponsors	61
Lost value of failed deals	61
<b>Main causes of biotech tech transfer failure</b>	<b>62</b>
Due diligence failures	64
Technology performance	66
Patent issues	67
Developer organization strength	67
Deal structure	69
Financial compensation	70
Management changes	71
Cultural differences	72
Project organization and expectations	74
Other preventable problems	76
Technology failure	77
<b>Conclusion</b>	<b>77</b>

## **Chapter 3                    Strategies to ensure successful biotech tech transfer deals                    80**

<b>Summary</b>	<b>80</b>
<b>Measures of success</b>	<b>81</b>
Success for the technology developer	81
Success for the technology sponsor	82
<b>Key biotech tech transfer strategies</b>	<b>82</b>
Strategies for both technology developers and sponsors	82
Meeting technology challenges	82
Strategies for technology developers	85
Optimizing resources	85
Thinking like a customer	88
Working with professional tech transfer organizations	89



## List of Figures

Figure 1.1:	Frequency of biotech tech transfer deals by type of institution	27
Figure 1.2:	Number and volume of biopartnering deals, 1997 - 2009	52
Figure 1.3:	Acquisitions as a proportion of biotech tech transfer deals,	53
Figure 2.4:	Characteristics of biotech tech transfer failure causes	63
Figure 2.5:	Relative importance to sponsor of technology developer	66
Figure 3.6:	Strategies to optimize biotech tech transfer opportunities	83
Figure 4.7:	Biopharmaceutical vs. other pharmaceutical sales, 2009 - 2015	124
Figure 4.8:	Impact of industry and economic trends on conventional and biotech drug developers, 2009 - 2015	125
Figure 4.9:	Relative importance of biotechnology for leading pharmaceutical companies, 2009 vs. 2015	127
Figure 4.10:	Number and average size of global biotech companies, 2009 - 2015	130
Figure 4.11:	Number and volume of biopartnering deals, 2009 - 2015	132

## List of Tables

Table 1.1:	Definition of biotechnology techniques	17
Table 1.2:	Biotech tech transfer deals, 2009	36
Table 1.3:	Biotech tech transfer deals, 2009 (Contd.)	37
Table 1.4:	Biotech tech transfer deals, 2009 (Contd.)	38
Table 1.5:	Biotech tech transfer deals, 2009 (Contd.)	39
Table 1.6:	Biotech tech transfer deals, 2009 (Contd.)	40
Table 1.7:	Biotech tech transfer deals, 2009 (Contd.)	41
Table 1.8:	Biotech tech transfer deals, 2009 (Contd.)	42
Table 1.9:	Biotech tech transfer deals, 2009 (Contd.)	43
Table 1.10:	Biotech tech transfer deals, 2009 (Contd.)	44
Table 1.11:	Biotech tech transfer deals, 2009 (Contd.)	45
Table 1.12:	Biotech tech transfer deals, 2009 (Contd.)	46
Table 1.13:	Biotech tech transfer deals, 2009 (Contd.)	47
Table 1.14:	Biotech tech transfer deals, 2009 (Contd.)	48
Table 1.15:	Biotech tech transfer deals, 2009 (Contd.)	49
Table 1.16:	Biotech tech transfer deals, 2009 (Contd.)	50
Table 3.17:	Technology transfer areas of interest for Merck & Co., 2010	95
Table 3.18:	Technology transfer areas of interest for Merck & Co., 2010 (Contd.)	96
Table 3.19:	Novartis private equity fund holdings, 2010	100
Table 3.20:	Novartis private equity fund holdings, 2010 (Contd.)	101
Table 3.21:	Novartis private equity fund holdings, 2010 (Contd.)	102
Table 3.22:	Novartis private equity fund holdings, 2010 (Contd.)	103
Table 4.23:	Millions of older and overweight persons in the US and EU, 2009 - 2015	119
Table 4.24:	Biosimilars approved in the US and EU, 2010	121